Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to characterize response to therapy_ ICARUS LUNG 01

2023-505924-71-00 Protocol CSET 2020/3187 Therapeutic exploratory (Phase II) Ongoing, recruiting

Start 12 May 2021 · Status Ongoing, recruiting · 1 EU/EEA countries · 9 sites · Protocol CSET 2020/3187

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruiting
Participants planned 100
Countries 1
Sites 9

Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

Key facts

Sponsor
Institut Gustave Roussy
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
12 May 2021 → ongoing
Decision date (initial)
2024-09-20
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-505924-71-00
EudraCT number
2020-005723-37

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable NSCLC

VersionLevelCodeTermSystem organ class
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut Gustave Roussy

Sponsor organisation
Institut Gustave Roussy
Address
114 Rue Edouard Vaillant
City
Villejuif
Postcode
94800
Country
France

Scientific contact point

Organisation
Institut Gustave Roussy
Contact name
Bureau projet Promotion- DRC

Public contact point

Organisation
Institut Gustave Roussy
Contact name
Bureau projet Promotion- DRC

Locations

1 EU/EEA country · 9 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 100 9
Rest of world 0

Investigational sites

France

9 sites · Ongoing, recruiting
Centre Hospitalier Regional Et Universitaire De Brest
Oncologie, 2 Avenue Marechal Foch, 29200, Brest
Hôpital Cochin
Oncologie, 27 rue du Fbg St Jacques, 75014, Paris
Centre Francois Baclesse
Oncologie, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5
Hospices Civils De Lyon
Oncologie, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Centre Hospitalier Intercommunal de Créteil
Oncologie, 40 Avenue De Verdun, 94000, Creteil
Institut Bergonie
Oncologie, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Institut Gustave Roussy
Oncologie, 114 Rue Edouard Vaillant, 94800, Villejuif
Les Hopitaux Universitaires De Strasbourg
Oncologie, 1 Place De L Hopital, Cs 80426, Strasbourg Cedex
Hopital Tenon
Oncologie, 4 Rue De La Chine, 75970, Paris Cedex 20

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2021-05-12 2021-05-12

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-08 France Acceptable
2024-09-16
2024-09-20
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-01 France Acceptable
2024-12-04
2025-01-10
3 SUBSTANTIAL MODIFICATION SM-3 2025-10-01 France Acceptable
2025-10-27
2025-10-27